This review highlights advances in the field of the local-regional treatment for patients with early-stage breast cancer. Through the years, the surgical treatment for early-stage breast cancer has evolved into more conservative treatment, with breast-conserving measures replacing the mastectomy as the most common procedure performed to treat the primary tumor. Likewise, nodal staging has evolved so that the lymphatic mapping procedures have replaced axillary dissection, resulting in a less morbid procedure and better staging information. Advances in radiation treatment have resulted in increasingly tailored approaches to adding radiation treatment after breast-conserving surgery or mastectomy. These improvements in local-regional treatment have benefitted patients through increased breast conservation treatment, improved local control, increased survival, and improved quality of life.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3816/CBC.2010.n.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Same-Day Access for Head and Neck Cancer: Effect on Patient Outcome and Quality-Related Benchmarks.
J Patient Exp
January 2025
Department of Radiation Oncology, Chao Family Comprehensive Cancer Center, University of California-Irvine, School of Medicine, Irvine, CA, USA.
Delays in cancer treatment are detrimental across nearly every disease site in oncology including head and neck cancer. This study aimed to evaluate the impact of same-day access for patients with newly diagnosed head and neck cancer referred for radiation therapy consultation. From March 2021 to March 2023, a total of 50 consecutive patients who completed curative treatment were matched to a control subject who did not use the same-day initiative based on age, gender, histology, performance status, primary tumor site, stage, p16 status, treatment, and smoking history.
View Article and Find Full Text PDFAssessment of viable tumours by [Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine and PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Purpose: To investigate the efficacy of [Ga]Ga-FAPI-04 PET/CT for assessing viable tumours (VTs) after local regional treatment (LRT) in hepatocellular carcinoma (HCC) patients. The related imaging features of HCC after LRT are preliminarily discussed.
Methods: A cohort of 37 LRT patients with HCC (encompassing 51 lesions) was retrospectively included from a prospective parent study (ChiCTR2000039099), and sequential PET/CT using [F]FDG and [Ga]Ga-FAPI-04 was performed.
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multi-center prospective cohort study.
Hepatology
January 2025
Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, CA.
Background Aims: Patients with hepatocellular carcinoma (HCC) meeting UNOS-downstaging (DS) criteria have excellent post-liver transplantation (LT) outcomes. Studies on HCC beyond UNOS-DS criteria ("All-comers" (AC)) have been limited by small sample size and short follow-up time, prompting this analysis.
Approach Results: 326 patients meeting UNOS-DS and 190 meeting AC criteria from 9 LT centers across 5 UNOS regions were enrolled from 2015 to 2023 and prospectively followed.
Predicting Postoperative Lung Cancer Recurrence and Survival Using Cox Proportional Hazards Regression and Machine Learning.
Cancers (Basel)
December 2024
Department of Radiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Background: Surgical resection remains the standard treatment for early-stage lung cancer. However, the recurrence rate after surgery is unacceptably high, ranging from 30% to 50%. Despite extensive efforts, accurately predicting the likelihood and timing of recurrence remains a significant challenge.
View Article and Find Full Text PDFHigh-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare.
JAMA Health Forum
January 2025
Department of Health Systems, Management, and Policy, University of Colorado Cancer Center, Aurora.
Importance: Medicare Advantage (MA) plans are designed to incentivize the use of less expensive drugs through capitated payments, formulary control, and preauthorizations for certain drugs. These conditions may reduce spending on high-cost therapies for conditions such as cancer, a condition that is among the most expensive to treat.
Objective: To determine whether patients insured by MA plans receive less high-cost drugs than those insured by traditional Medicare (TM).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!